Marsh & McLennan Companies, Inc. has completed the acquisition of Jardine Lloyd Thompson Group plc (JLT) for $5.6 billion in fully diluted equity value, furthering its role as the world’s preeminent professional services firm in the areas of risk, strategy and people.
“Today marks the beginning of a new era with Marsh & McLennan and JLT coming together. This is a combination of strength and strength, and the primary focus is growth – in talent, capabilities, revenue and earnings,” said Dan Glaser, President and Chief Executive Officer, Marsh & McLennan Companies.
Market Leader in Risk, Strategy & People
The acquisition advances Marsh & McLennan’s leadership position in insurance and reinsurance brokerage, health and retirement. Its global reach spans more than 130 countries. Marsh & McLennan Companies advises 95 percent of the Fortune 1000®1 and has significantly expanded its presence in the middle market and small commercial segments. The combined company provides advice and solutions for more than $100 billion of annual property/casualty insurance and reinsurance premiums placed globally.
Formidable Collection of Talent
JLT brings Marsh & McLennan a significant influx of talent – more than 10,000 colleagues – providing deeper industry expertise in almost every part of the organization. The combination will create more opportunities for colleagues. Many of JLT’s top executives have been named to leadership positions at Marsh & McLennan, Marsh, Guy Carpenter and Mercer including former JLT CEO Dominic Burke, who joins Marsh & McLennan as Vice Chairman and a member of the Executive Committee. Mr. Glaser said, “Our aspiration is to shape our industries and be the employer of choice.”
Enhancing Capabilities, Growth & Investment in Data & Analytics
The acquisition builds on Marsh & McLennan’s efforts to expand in faster-growing geographies and market segments and invest in data and analytics while enhancing its capabilities across insurance brokerage, retirement and benefits.
Financially Attractive for Shareholders
As previously announced, the transaction is expected to be immediately accretive to adjusted cash EPS and, as modeled, will produce a double-digit internal rate of return. On an adjusted GAAP EPS basis, the deal is expected to be modestly dilutive in year one, neutral in year two, and accretive in year three.
Latest from iPMI Magazine
- Costa Fortune – Every 3 Minutes A UK Traveller Now Needs Emergency Medical Treatment Abroad, As The Medical Treatment Bill Hits An 8 Year High
- How Safe Is It To Visit Hong Kong?
- Now Health International Bolsters Senior Leadership Team With Strategic Hire
- Latest ABI Analysis Underlines Importance Of Preparing For Business Travel Risks
- iPMI Magazine Speaks With Janette Hiscock, CEO Of Global Solutions Europe, United Healthcare Global